SLS SELLAS Life Sciences Group, Inc. - Common Stock
SELLAS Life Sciences Group, Inc. - Common Stock 정보 위키백과 회사 개요
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
더 보기
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
SLS 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
SLS 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
SLS 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 1 16.7%
- 매수 4 66.7%
- 보유 1 16.7%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
2 명의 애널리스트 · 2026-08-14실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 3월 31일 | $-0.05 | $-0.04 | -0.01% |
| 2025년 12월 31일 | $-0.05 | $-0.07 | 0.02% |
| 2025년 9월 30일 | $-0.06 | $-0.07 | 0.01% |
| 2025년 6월 30일 | $-0.07 | $-0.08 | 0.01% |
| 2025년 3월 31일 | $-0.07 | $-0.11 | 0.04% |
| 2024년 12월 31일 | $-0.08 | $-0.11 | 0.03% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| IRON | $3.01B | -13.2 | — | — | -31.3% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 15
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
대차대조표 22
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
현금 흐름 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
유동성 및 지급능력 4
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
효율성 1
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
성장률 1
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
가치 평가 (TTM) 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
손익계산서 12
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
대차대조표 15
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
현금 흐름 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
수익성 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
유동성 및 지급능력 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
효율성 1
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
가치 평가 (TTM) 9
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | — | — | $0 | $1M | $8M |
| 영업이익률 % | — | — | — | -4195.0% | -332.8% |
| 순이익 | $-27M | $-31M | $-37M | $-41M | $-21M |
| 희석 EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| 당좌 비율 | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 232개의 제출자 · $1.2B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 87 (+24 이전 분기 대비) | 19 (+4 이전 분기 대비) | 70 (+12 이전 분기 대비) | 38 (+15 이전 분기 대비) | +39.9M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| STATE STREET CORP | $191,829,196 | 12,996,558 | 15.97% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $121,417,310 | 8,226,105 | 10.11% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105,640,272 | 7,157,200 | 8.79% | 콜 옵션 |
| Anson Funds Management LP | $66,420,000 | 4,500,000 | 5.53% | 주식 |
| CITADEL ADVISORS LLC | $64,157,292 | 4,346,700 | 5.34% | 콜 옵션 |
| GEODE CAPITAL MANAGEMENT, LLC | $61,905,400 | 4,193,009 | 5.15% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61,832,592 | 4,189,200 | 5.15% | 풋 옵션 |
| CITADEL ADVISORS LLC | $33,333,984 | 2,258,400 | 2.77% | 풋 옵션 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31,897,821 | 2,161,099 | 2.66% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30,266,812 | 2,050,597 | 2.52% | 주식 |
| JONES FINANCIAL COMPANIES LLLP | $28,553,511 | 2,304,561 | 2.38% | 주식 |
| VANGUARD GROUP INC | $27,868,421 | 7,392,154 | 2.32% | 주식 |
| Anson Funds Management LP | $27,245,484 | 1,845,900 | 2.27% | 풋 옵션 |
| PERCEPTIVE ADVISORS LLC | $22,140,000 | 1,500,000 | 1.84% | 풋 옵션 |
| VANGUARD FIDUCIARY TRUST CO | $19,707,050 | 1,335,166 | 1.64% | 주식 |
| Sio Capital Management, LLC | $18,165,132 | 1,230,700 | 1.51% | 풋 옵션 |
| BNP PARIBAS FINANCIAL MARKETS | $15,823,045 | 1,072,022 | 1.32% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $13,372,560 | 906,000 | 1.11% | 풋 옵션 |
| BARCLAYS PLC | $11,831,616 | 801,600 | 0.98% | 풋 옵션 |
| Anson Funds Management LP | $11,808,000 | 800,000 | 0.98% | 콜 옵션 |
| BNP PARIBAS FINANCIAL MARKETS | $11,734,200 | 7,950 | 0.98% | 풋 옵션 |
| JANE STREET GROUP, LLC | $11,058,192 | 749,200 | 0.92% | 콜 옵션 |
| MORGAN STANLEY | $9,922,380 | 672,248 | 0.83% | 주식 |
| BANK OF AMERICA CORP /DE/ | $9,150,359 | 619,943 | 0.76% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8,339,518 | 565,008 | 0.69% | 주식 |
| JANE STREET GROUP, LLC | $7,462,700 | 505,603 | 0.62% | 주식 |
| Balyasny Asset Management L.P. | $7,380,000 | 500,000 | 0.61% | 풋 옵션 |
| LMR Partners LLP | $6,642,000 | 450,000 | 0.55% | 풋 옵션 |
| NOMURA HOLDINGS INC | $6,273,000 | 425,000 | 0.52% | 콜 옵션 |
| DIADEMA PARTNERS LP | $5,904,000 | 400,000 | 0.49% | 콜 옵션 |
| Swiss National Bank | $5,319,504 | 360,400 | 0.44% | 주식 |
| XTX Topco Ltd | $5,300,168 | 359,090 | 0.44% | 주식 |
| Ikarian Capital, LLC | $5,235,372 | 354,700 | 0.44% | 풋 옵션 |
| CITIGROUP INC | $4,659,717 | 315,699 | 0.39% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $4,580,973 | 310,364 | 0.38% | 주식 |
| DAGCO, INC. | $4,351,740 | 1,028,780 | 0.36% | 주식 |
| Everhart Financial Group, Inc. | $4,251,146 | 288,018 | 0.35% | 주식 |
| Rafferty Asset Management, LLC | $3,540,806 | 239,892 | 0.29% | 주식 |
| RHUMBLINE ADVISERS | $3,400,726 | 230,402 | 0.28% | 주식 |
| Walleye Capital LLC | $3,377,088 | 228,800 | 0.28% | 풋 옵션 |
| GOLDMAN SACHS GROUP INC | $3,125,991 | 211,788 | 0.26% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $3,087,792 | 209,200 | 0.26% | 풋 옵션 |
| WELLINGTON MANAGEMENT GROUP LLP | $2,992,738 | 202,760 | 0.25% | 주식 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2,982,996 | 202,100 | 0.25% | 풋 옵션 |
| Jefferies Financial Group Inc. | $2,958,775 | 200,459 | 0.25% | 주식 |
| Jefferies Financial Group Inc. | $2,953,476 | 200,100 | 0.25% | 풋 옵션 |
| Mariner, LLC | $2,925,609 | 198,212 | 0.24% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $2,895,912 | 196,200 | 0.24% | 콜 옵션 |
| Bank of New York Mellon Corp | $2,801,212 | 189,784 | 0.23% | 주식 |
| ALPS ADVISORS INC | $2,776,459 | 188,107 | 0.23% | 주식 |
| JANE STREET GROUP, LLC | $2,405,880 | 163,000 | 0.20% | 풋 옵션 |
| LPL Financial LLC | $2,297,586 | 155,663 | 0.19% | 주식 |
| SIMPLEX TRADING, LLC | $2,274,501 | 154,099 | 0.19% | 주식 |
| BlackRock, Inc. | $2,222,708 | 150,590 | 0.19% | 주식 |
| WELLS FARGO & COMPANY/MN | $2,208,775 | 149,646 | 0.18% | 주식 |
| Vontobel Holding Ltd. | $2,166,207 | 146,762 | 0.18% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $2,069,352 | 140,200 | 0.17% | 콜 옵션 |
| Vanguard Global Advisers, LLC | $1,918,874 | 130,005 | 0.16% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $1,859,598 | 125,989 | 0.15% | 주식 |
| Caption Management, LLC | $1,845,000 | 125,000 | 0.15% | 풋 옵션 |
| PROFUND ADVISORS LLC | $1,780,159 | 120,607 | 0.15% | 주식 |
| MetLife Investment Management, LLC | $1,624,810 | 110,082 | 0.14% | 주식 |
| Daiwa Securities Group Inc. | $1,589,652 | 107,700 | 0.13% | 풋 옵션 |
| Daiwa Securities Group Inc. | $1,512,900 | 102,500 | 0.13% | 주식 |
| DIADEMA PARTNERS LP | $1,476,000 | 100,000 | 0.12% | 풋 옵션 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1,467,144 | 99,400 | 0.12% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,405,300 | 95,210 | 0.12% | 주식 |
| Harvest Investment Services, LLC | $1,394,554 | 94,482 | 0.12% | 주식 |
| ORBIMED ADVISORS LLC | $1,365,300 | 92,500 | 0.11% | 풋 옵션 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1,229,582 | 83,305 | 0.10% | 주식 |
| Invesco Ltd. | $1,104,816 | 74,852 | 0.09% | 주식 |
| Gotham Asset Management, LLC | $1,097,317 | 74,344 | 0.09% | 주식 |
| FULCRUM WEALTH ADVISORS, LLC | $1,081,214 | 73,253 | 0.09% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $998,534 | 236,060 | 0.08% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $978,588 | 66,300 | 0.08% | 주식 |
| Verition Fund Management LLC | $916,596 | 62,100 | 0.08% | 풋 옵션 |
| OSAIC HOLDINGS, INC. | $889,776 | 60,284 | 0.07% | 주식 |
| FIFTH THIRD BANCORP | $888,404 | 60,190 | 0.07% | 주식 |
| State of New Jersey Common Pension Fund D | $857,069 | 58,067 | 0.07% | 주식 |
| Verition Fund Management LLC | $832,464 | 56,400 | 0.07% | 콜 옵션 |
| Police & Firemen's Retirement System of New Jersey | $821,630 | 55,666 | 0.07% | 주식 |
| ARIZONA STATE RETIREMENT SYSTEM | $731,388 | 49,552 | 0.06% | 주식 |
| Caption Management, LLC | $728,745 | 49,373 | 0.06% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722,310 | 48,937 | 0.06% | 주식 |
| Russell Investments Group, Ltd. | $704,494 | 47,730 | 0.06% | 주식 |
| SIG BROKERAGE, LP | $689,292 | 46,700 | 0.06% | 콜 옵션 |
| Vanguard Investments Australia, Ltd. | $684,643 | 46,385 | 0.06% | 주식 |
| COMMONWEALTH EQUITY SERVICES, LLC | $665,481 | 45,087 | 0.06% | 주식 |
| INSTRUMENTAL WEALTH, LLC | $662,931 | 44,914 | 0.06% | 주식 |
| Persistent Asset Partners Ltd | $655,647 | 758 | 0.05% | 콜 옵션 |
| Virtus Investment Advisers, LLC | $616,791 | 41,788 | 0.05% | 주식 |
| Accurate Wealth Management, LLC | $614,707 | 47,462 | 0.05% | 주식 |
| AXXCESS WEALTH MANAGEMENT, LLC | $610,665 | 41,373 | 0.05% | 주식 |
| KLP KAPITALFORVALTNING AS | $600,732 | 40,700 | 0.05% | 주식 |
| SJS Investment Consulting Inc. | $590,400 | 40,000 | 0.05% | 주식 |
| Wealthfront Advisers LLC | $587,773 | 39,822 | 0.05% | 주식 |
| Quantinno Capital Management LP | $546,651 | 37,036 | 0.05% | 주식 |
| Visionary Horizons, LLC | $531,360 | 36,000 | 0.04% | 주식 |
| Kestra Advisory Services, LLC | $516,305 | 34,980 | 0.04% | 주식 |
| NORTHSTAR ASSET MANAGEMENT Co | $509,400 | 45,000 | 0.04% | 주식 |
회사 내부자 42 명의 내부자 · 17 임원 · 9 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 2026년 6월 16일 A | 1,759,183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 2011년 3월 15일 A | 92,994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 2026년 1월 7일 A | 554,327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 2018년 4월 20일 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 2011년 4월 13일 A | 379,294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 2009년 1월 15일 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 2026년 1월 7일 A | 557,805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 2024년 1월 22일 A | 40,918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 2024년 1월 22일 A | 117,225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 2019년 3월 14일 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 2018년 3월 13일 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 2011년 3월 15일 A | 14,065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 2011년 3월 15일 A | 41,083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 2011년 3월 15일 A | 60,559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 2011년 3월 15일 A | 44,940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 2010년 4월 15일 A | 5,750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 2010년 3월 31일 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | 이사 | 2026년 1월 7일 A | 154,400 | 1 | 0 | $100,806 |
| John Varian | 이사 | 2026년 1월 7일 A | 72,900 | 0 | 0 | $0 |
| Jane Wasman | 이사 | 2026년 1월 7일 A | 92,900 | 0 | 0 | $0 |
| David A Scheinberg | 이사 | 2026년 1월 7일 A | 73,082 | 0 | 0 | $0 |
| Robert L Van Nostrand | 이사 | 2026년 1월 7일 A | 82,900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | 이사 | 2019년 3월 14일 A | — | 0 | 0 | $0 |
| Fabio Lopez | 이사 | 2018년 6월 12일 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 2017년 10월 10일 A | 34,690 | 0 | 0 | $0 |
| William Ashton | — | 2017년 10월 10일 A | 38,154 | 0 | 0 | $0 |
| Richard Chin | — | 2017년 10월 10일 A | 31,339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 2017년 10월 10일 A | 42,918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 2017년 10월 10일 A | 56,950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 2017년 10월 10일 A | 39,167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 2017년 10월 10일 A | 36,039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 2017년 2월 6일 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 2017년 1월 17일 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 2016년 6월 1일 M | 18,702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 2015년 12월 18일 A | 415,972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 2015년 6월 19일 A | 5,000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 2015년 1월 16일 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 2014년 6월 30일 J | 2,461 | 0 | 0 | $0 |
| Mark J Ahn | — | 2014년 6월 30일 A | 116,225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 2013년 1월 29일 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 2010년 12월 29일 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 2009년 1월 15일 A | — | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 2 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 제출 서류 | 2018년 10월 10일 | — | 최초 제출 | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 2018년 1월 8일 | — | 최초 제출 | M&A / 매각 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 29 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0.77% | 288,499 SH | 2026년 8월 8일 | 일간 |
| IWC · iShares Trust | 0.50% | 640,415 SH | 2026년 8월 8일 | 일간 |
| LABU · Direxion Shares ETF Trust | 0.26% | 268,465 NS | 2026년 4월 30일 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.23% | 316,525 SH | 2026년 8월 8일 | 일간 |
| ICOP · iShares Trust | 0.22% | 126,361 SH | 2026년 8월 8일 | 일간 |
| CANC · Tema ETF Trust | 0.22% | 40,702 NS | 2026년 5월 31일 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.16% | 202,339 SH | 2026년 8월 8일 | 일간 |
| IWO · iShares Trust | 0.14% | 1,712,069 SH | 2026년 8월 8일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.08% | 1,086,285 SH | 2026년 8월 8일 | 일간 |
| IWM · iShares Trust | 0.07% | 4,828,431 SH | 2026년 8월 8일 | 일간 |
| ISCG · iShares Trust | 0.07% | 57,511 SH | 2026년 8월 8일 | 일간 |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 51,293 NS | 2026년 5월 31일 | N-PORT |
| PICK · iShares, Inc. | 0.04% | 122,564 SH | 2026년 8월 8일 | 일간 |
| ITWO · ProShares Trust | 0.04% | 8,088 NS | 2026년 5월 31일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.04% | 540,244 SH | 2026년 8월 8일 | 일간 |
| ISCF · iShares Trust | 0.04% | 30,200 SH | 2026년 8월 8일 | 일간 |
| ISCB · iShares Trust | 0.03% | 8,283 SH | 2026년 8월 8일 | 일간 |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2,134,285 SH | 2026년 8월 8일 | 일간 |
| WSML · iShares Trust | 0.03% | 16,889 SH | 2026년 8월 8일 | 일간 |
| RSSL · Global X Funds | 0.03% | 74,459 NS | 2026년 4월 30일 | N-PORT |
| UWM · ProShares Trust | 0.02% | 6,326 NS | 2026년 5월 31일 | N-PORT |
| URTY · ProShares Trust | 0.02% | 6,397 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.01% | 161 NS | 2026년 5월 31일 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 64,480 NS | 2026년 5월 31일 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3,554 NS | 2026년 5월 31일 | N-PORT |
| ITOT · iShares Trust | 0.00% | 273,812 SH | 2026년 8월 8일 | 일간 |
| IWV · iShares Trust | 0.00% | 43,929 SH | 2026년 8월 8일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5,908,560 SH | 2026년 8월 8일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 15,706 SH | 2026년 8월 8일 | 일간 |